Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/22142
Title: Design and syntheses of permethyl ningalin B analogues : potent multidrug resistance (MDR) reversal agents of cancer cells
Authors: Zhang, PY
Wong, ILK
Yan, CSW
Zhang, XY
Jiang, T
Chow, LMC 
Wan, SB
Issue Date: 2010
Publisher: Amer Chemical Soc
Source: Journal of medicinal chemistry, 2010, v. 53, no. 14, p. 5108-5120 How to cite?
Journal: Journal of Medicinal Chemistry 
Abstract: A series of novel N-arylalkyl-3,4-diaryl-substituted pyrrole-2,5-diones were synthesized. They exhibited promising P-gp modulating activity in a P-gp overexpressing breast cancer cell line (LCC6MDR). Compound 6 (with three methoxy groups at D-ring) displayed the highest P-gp modulating activity. 6 at 1 μM can sensitize LCC6MDR cells toward paclitaxel by 18.2-fold. Interestingly, a synergy on modulating P-gp was noted when 6 and 25 were used together (fractional inhibitory concentration index FICI = 0.42). Combination of 6 (0.5 μM) and 25 (0.5 μM) resulted in a 66-fold sensitization of LCC6MDR cells toward paclitaxel. They also reversed P-gp mediated doxorubicin (DOX) and vincristine resistance. Kinetic characterization suggests that permethyl ningalin B analogues likely act as a noncompetitive inhibitor of P-gp-mediated DOX transport (K i = 5.4-5.8 μM). The present study demonstrates that synthetic analogues of permethyl ningalin B can be employed as effective and safe modulators of P-gp-mediated drug resistance in cancer cells.
URI: http://hdl.handle.net/10397/22142
DOI: 10.1021/jm100035c
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

33
Last Week
0
Last month
0
Citations as of Aug 20, 2017

WEB OF SCIENCETM
Citations

30
Last Week
0
Last month
0
Citations as of Aug 20, 2017

Page view(s)

49
Last Week
0
Last month
Checked on Aug 20, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.